MedTrace Logo

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

NCT04221152 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-06-03

No results posted yet for this study

Summary

A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.

Conditions

  • Insulin Resistance - Type A
  • Insulin Resistance - Type B
  • Lipoatrophic Diabetes Mellitus
  • Insulin Resistance Syndrome

Interventions

DRUG

Empagliflozin Tablets

The administration is oral administration with water before or after breakfast.

Sponsors & Collaborators

Principal Investigators

  • Wataru Ogawa · Kobe University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-02-01
Completion
2022-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221152 on ClinicalTrials.gov